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Abstract: 
We report a case of hypersensitivity pneumonitis in a young person secondary to vaping. He 
presented with a putative diagnosis of asthma and required Extracorporeal Membrane 
Oxygenation (ECMO) because of intractable respiratory failure. He developed a critical 
illness and steroid myopathy and required prolonged rehabilitation. Our patient fulfils 
diagnostic criteria for hypersensitivity pneumonitis (HP) secondary to e-cigarettes with a 
positive exposure history, deterioration after skin prick testing, specific serum IgM 
antibodies against the implicated liquid raising the possibility that the relevant antigen was 
present in that liquid and radiological and histopathological features compatible with acute 
HP. There are two learning points. The first is always to consider a reaction to e-cigarettes in 
someone presenting with an atypical respiratory illness. The second is that we consider e-
cigarettes as ‘much safer than obacco’ at our peril.
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Introduction:
Hypersensitivity Pneumonitis (HP) is an immune mediated reaction that follows the 
inhalation of antigens or chemicals and mainly affects the alveoli, interstitium and 
bronchioles. There are two main categories of HP: Acute/inflammatory and Chronic/fibrotic  
(1). Putative antigen triggers are diverse and the list is ever increasing. Pathogenesis is 
attributed t  a combination of type III (immune complex–mediated) and type IV (delayed) 
hypersensitivity reactions. Though any environment with sufficient amount of antigen can 
cause HP, there is evidence that a second hit such as viral infection or endotoxin exposure 
may be needed to in uce the disease. 
Flavoured e-cigarettes liquids contain airway irritants and toxicants such as propylene glycol 
(PG), vegetable glycerine (VG), and many different flavouring chemicals that have been 
implicated in the pathogenesis and worsening of lung diseases, and which likely induce 
respiratory effects not seen in tobacco smokers. Additionally thermal decomposition of PG 
and VG, the base constituents of e-liquids, produces reactive carbonyls, including acrolein, 
formaldehyde, and acetaldehyde, which have known respiratory toxicities (2). It is possible 
that the pulmonary manifestations associated with vaping represent a range of disease 
processes. What is important however that clinicians should consider the possibility of 
pulmonary disease associated with vaping when patients report recent use, especially when 
other causes are not identified as the recent epidemic highlights (3). 
Case:
A previously healthy 16 year old boy presented to the emergency department with a 7 day 
history of fever, cough and increasing difficulty breathing despite oral antibiotics and 
inhaled salbutamol. There was no previous confirmed diagnosis of asthma and he was not 
on any regular controller treatment with inhaled corticosteroids. He deteriorated rapidly 
and required non-invasive, conventional and, then high frequency oscillation ventilation and 
finally transfer for ECMO because of intractable respiratory failure. He had 3 days of 
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venovenous ECMO, and treatment with broad spectrum intravenous antibiotics, 
intravenous hydrocortisone, a macrolide and antifungals. He was stepped down to the 
paediatric respiratory ward 10 days after his admission on 4 litres/minute nasal cannula 
oxygen, and inhaled bronchodilators and oral corticosteroids for a putative diagnosis of 
asthma. He developed a critical illness and steroid myopathy and required prolonged 
rehabilitation.
Further questioning revealed that he had recently started to use e-cigarettes fairly 
frequently, using two different liquids, purchased over the counter. During his 
convalescence he mentioned that at some point he had used both the liquids in question 
though was unable to r collect the exact sequence of use and in particular which one he 
had used immediately prior to becoming unwell. The listed ingredients of both the liquids 
were identical except for the un-named flavourings (see below).
He had smoked cannabis a year previously but not recently. He had no recent bird or farm 
animal exposure or any recent travel.
The results of the investigations during his acute illness were: 
 A CT chest 6 days after admission (Figure 1) showed bilateral ground glass changes in 
the upper and mid-zones with perihilar bronchial wall thickening and retained 
secretions in the dependant airways. 
 Bronchoalveolar lavage (BAL) in PICU and a later expectorated sputum sample both 
showed moderate numbers of  macrophages, neutrophils  and eosinophils (20%) – 
consistent with active inflammation.
 First spirometry 22 days after admission showed Forced Expiratory Volume in 1 s 
(FEV1) was 3.52 L, z score -1.91 and Forced Vital Capacity (FVC) 3.68 L, z score -2.73. 
Total Lung Capacity (Helium dilution) was 5.91 L, z score -0.82 and transfer factor, 
TLCOc SB [mmol/min/kPa) was 9.02, z score -0.92.  
 The only evidence of infection was a nasopharyngeal aspirate positive for Rhinovirus.  
 He had a raised C-reactive protein, but negative tests for autoimmune disease, 
vasculitis and avian precipitins. 
 He had a negative skin prick test (SPT) to e-cigarettes Liquid 1 and Liquid 2 (with 
identical ingredients but different flavourings: 0.3 % nicotine, VG, mono-PG, 
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flavourings; neither had a comprehensive list of ingredients) the positive control was 
5 mm; so the clinical picture was not that of IgE mediated reaction. However, this 
does not exclude an adverse reaction to e-cigarettes. Indeed, eight hours after SPT 
he deteriorated with chest tightness, difficulty breathing and widespread wheeze 
requiring oxygen, intravenous and nebulised salbutamol and an increased dose of 
oral steroids. We postulated that this exacerbation of symptoms occurred due to 
antigen re-exposure in the setting of  his pre-existing acute HP (4) with the eliciting 
antigen in either or both of the E-cigarette liquids.   
He was discharged home 35 days after admission with a plan to slowly taper oral steroids. 
This led to worsening respiratory status and he returned to the emergency department on 
one occasion and was admitted on other requiring intensive treatment for respiratory 
distress and wheeze. He was categorical that he had not used any more e-cigarettes and 
there were no other obvious triggers in the environment; however we did not specifically 
test him for any respiratory viruses and the clinical worsening was attributed to a too rapid 
taper of steroids. He had a repeat CT chest 44 days after presentation (Figure 1) which 
showed patchy areas of ground glass opacification throughout both lungs which had 
improved considerably since the previous scan but there were ground glass appearances in 
new areas including the right lower lobe. 
A surgical lung biopsy was obtained 50 days after his first presentation as he continued to 
be symptomatic and further treatment with pulsed methylprednisolone was contemplated. 
The biopsy showed (Figure 1): alveolar spaces containing macrophages and evidence of 
haemorrhage. A few alveolar spaces lined by fibrin suggesting early hyaline membrane 
formation. No granulomas were identified. Of note, the lung biopsy and the CT appearances 
are likely to have been modified by the very significant ventilation and high doses of 
steroids. 
The presence of an eliciting antigen in either or both of the E-cigarette liquids was further 
investigated by developing an in-house enzyme-linked immunosorbent assay (ELISA) to 
detect antibodies specific to the E-cigarette liquid constituents. Serum samples were 
obtained from the patient on day 50 (no serum was available for analysis of the 
immunological assay in the academic department prior to Day 50) and 112 days from 1st 
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presentation, the latter following treatment with high dose pulsed methylprednisolone and 
abstinence from E-cigarettes. Sera were also obtained from five healthy donors (median age 
21 years old, range 20-23; 3 male and 2 female) who had never smoked tobacco or used E-
cigarettes. 
IgG antibodies binding to both E-cigarette liquids were detected at similar levels in all serum 
samples (from both the patient and the controls), suggesting the presence of cross-reactive 
antibodies in all individuals.  As shown in Figure 1, fewer samples were positive for specific 
IgM antibodies and the patient had IgM specific for Liquid 1, but not Liquid 2, raising the 
possibility that the eliciting antigen was present in Liquid 1.  Healthy control 1 also had IgM 
antibodies specific for Liquid 1, again suggesting the occurrence of cross-reactive antibodies 
in some non-exposed individuals.
Fourteen months after the initial presentation, he was asymptomatic with normal 
spirometry (FEV1 4.35 L, z score -0.65 and FVC 5.12 L, z score -0.16).
Discussion:
This previously well young person presented with a catastrophic respiratory illness. For such 
to be the very first presentation of asthma would be virtually unheard of. 
Our patient fulfils diagnostic criteria for HP secondary to e-cigarettes. There was a positive 
exposure history, and importantly, deterioration after SPT. We detected serum IgM 
antibodies against the implicated liquid raising the possibility that the eliciting antigen was 
present in the vaping liquid, however we acknowledge these are not specific, being present 
in a control ; a previous patient had no supportive immunological evidence (5). Antibodies 
associated with HP are usually of IgG class, IgM class antibodies can also be involved (6). 
The CT pattern was typical for acute HP with ground glass opacities predominantly in upper 
and middle lobes and mosaic attenuation; other features such as centrilobular diffuse 
micronodular pattern were not seen, likely because of previous corticosteroid therapy. The 
histopathology was compatible, but the pathological features of acute HP are poorly 
characterized because patients are rarely (if ever) biopsied. Findings include intra-alveolar 
fibrin, neutrophil accumulation with or without findings of acute lung injury, and possible 
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small vessel vasculitis; poorly formed, non-necrotising, granulomas may be seen (4,7). Our 
patient had evidence of inflammation (BAL and biopsy) and hyaline membrane formation
Conclusions:
There are two important lessons here. The first is always to consider a reaction to e-
cigarettes in someone presenting with an atypical respiratory illness. The second is that we 
consider e-cigarettes as ‘much safer than tobacco’ at our peril.
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Figure 1: Radiology - immunology--histopathology correlation in a case of hypersensitivity 
pneumonitis: 
Concentration of Liquid 1 specific IgM.
Concentration of Liquid 2 specific IgM. 
First CT scan, day 6 from first presentation. 
Second CT scan, day 44 from first presentation. 
Lung biopsy showing inflammation and hyaline membrane formation
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Figure 1: Radiology - immunology--histopathology correlation in a case of hypersensitivity pneumonitis: 
Concentration of Liquid 1 specific IgM. 
Concentration of Liquid 2 specific IgM. 
First CT scan, day 6 from first presentation. 
Second CT scan, day 44 from first presentation. 
Lung biopsy showing inflammation and hyaline membrane formation 
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